The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis by Qiliu Peng et al.
Peng et al. Diagnostic Pathology 2014, 9:100
http://www.diagnosticpathology.org/content/9/1/100RESEARCH Open AccessThe NQO1 Pro187Ser polymorphism and breast
cancer susceptibility: evidence from an updated
meta-analysis
Qiliu Peng1, Yu Lu1, Xianjun Lao1, Zhiping Chen2, Ruolin Li3, Jingzhe Sui1, Xue Qin1* and Shan Li1Abstract
Background: NAD(P)H: quinone oxidoreductase 1 (NQO1) plays a central role in catalyzing the two-electron
reduction of quinoid compounds into hydroquinones. The NQO1 Pro187Ser polymorphism was found to correlate
with a lower enzymatic activity, which may result in increased incidence of carcinomas including breast cancer.
Previous studies investigating the association between NQO1 Pro187Ser polymorphism and breast cancer risk
showed inconsistent results. We performed a meta-analysis to summarize the possible association.
Methods: All studies published from January 1966 to February 2014 on the association between NQO1 Pro187Ser
polymorphism and breast cancer risk were identified by searching electronic databases PubMed, EMBASE, Cochrane
library, and Chinese Biomedical Literature database (CBM). The association between NQO1 Pro187Ser polymorphism
and breast cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).
Results: Ten studies with 2,773 cases and 4,076 controls were finally included in the meta-analysis. We did not
observe a significant association between NQO1 Pro187Ser polymorphism and breast cancer risk when all studies
were pooled into the meta-analysis. In subgroup analysis by ethnicity, significant increased breast cancer risk was
found in Caucasians (Ser/Pro vs. Pro/Pro: OR = 1.145, 95% CI = 1.008–1.301, P = 0.038; Ser/Ser + Ser/Pro vs. Pro/Pro:
OR = 1.177, 95% CI = 1.041–1.331, P = 0.009). When stratified by source of control, significant increased breast cancer
risk was found in population-based studies (Ser/Pro vs. Pro/Pro: OR = 1.180, 95% CI = 1.035–1.344, P = 0.013;
Ser/Ser + Ser/Pro vs. Pro/Pro: OR = 1.191, 95% CI = 1.050–1.350, P = 0.007). However, in subgroup analyses according
to menopausal status, quality score, and HWE in controls, no any significant association was detected.
Conclusions: Our meta-analysis provides the evidence that the NQO1 Pro187Ser polymorphism contributed to the
breast cancer susceptibility among Caucasians. Further large and well-designed studies are needed to confirm this
association.
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Breast cancer is the most common cancer and the se-
cond most common cause of cancer-related death in
women. In 2008 there were 182,460 women diagnosed
with breast cancer, and 40,480 women died of this dis-
ease [1]. In several developing countries, such as China,
breast cancer has surpassed cervical cancer and become
the leading cause of cancer death among females [2].
Though the exact mechanism of breast carcinogenesis is
still unclear, it has been well accepted that oxidative
stress resulting from excess reactive oxygen species
and deficiency in antioxidant capabilities play important
roles in breast cancer etiology [3,4].
NAD(P)H:quinone oxidoreductase 1 (NQO1), also
known as diphtheria toxin diaphorase (DT-diaphorase), is
a cytosolic flavoenzyme which is present in human epi-
thelial and endothelial tissues. NQO1 is considered as an
anticancer enzyme because it protect cells from oxidative
damage by preventing quinones from entering the one-
electron reduction which is catalyzed by cytochrom b5
reductase or P450 reductase to generate semiquinone free
radicals and reactive oxygen species [5]. On the contrary,
with its unique property of transferring two electrons at a
time by using either NADH or NADPH as reducing cofac-
tor, NQO1 catalyze quinones and quinine-imines into hy-
droquinones, which are thought less toxic and easier to
excrete when conjugated [6,7]. The NQO1 gene, mapped
to chromosome 16q22.1, is 17.2 kb in length and contains
6 exons and 5 introns [8]. There were at least 270 SNPs in
the NQO1 gene according to the dbSNP database (http://
www.ncbi.nlm.nih.gov/SNP), including the most com-
monly occurring C-to-T transition at nucleotide position
609 in exon 6 (rs1800566, 609C > T), which results in a
proline-to-serine amino-acid substitution at codon 187
(Pro187Ser) in the protein. It was reported that the variant
T allele was associated with reduced NQO1 enzymatic ac-
tivity in both human cell lines and primary human tissues
[9,10]. Furthermore, there is a clear allele dosage effect of
the NQO1 609 T genotypes on NQO1 enzymatic activity,
with the variant homozygotes (TT) having the lowest, the
heterozygotes (CT) having the intermediate, and the wild-
type homozygotes (CC) having the highest NQO1 enzyme
activity [11-13]. Given that the previous studies have
consistently shown that the variant T allele resulted in re-
duced enzymatic activity, it was biologically reasonable to
hypothesize a potential relationship between the NQO1
Pro187Ser polymorphism and cancer susceptibility.
In the past two decades, a number of molecular
epidemiological studies have evaluated the association
between the NQO1 Pro187Ser polymorphism and breast
cancer risk, but the results remain inconsistent. Several
studies have previously suggested that the NQO1
Pro187Ser polymorphism was associated with an in-
creased risk of breast cancer [14,15]. However, otherstudies have failed to confirm such an association [3,16].
In addition, a meta-analysis by Yuan et al. [17] found that
the NQO1 Pro187Ser polymorphism may contribute to
breast cancer development in Caucasians. However, evi-
dence was limited because only 6 studies were available at
that time. In addition, only ethnicity was considered in the
subgroup analysis and the source of heterogeneity was not
explored in this study. As some new studies emerging
[16,18,19], to provide the most comprehensive assessment
of the associations between the NQO1 Pro187Ser poly-
morphism and breast cancer risk, we performed an up-
dated meta-analysis of all available studies with extensive




We conducted a comprehensive literature search in
PubMed, EMBASE, Cochrane library, and Chinese Bio-
medical Literature (CBM) databases form January 1966 to
February 2014 using the following search strategy: (“breast
cancer”) and (“NAD(P)H:quinone oxidoreductase 1”, or
“NQO1”). There was no restriction on sample size, popu-
lation, language, or type of report. All eligible studies were
retrieved and their references were checked for other
relevant studies. The literature retrieval was performed in
duplication by two independent reviewers (Qiliu Peng and
Yu Lu). When multiple publications reported on the same
or overlapping data, we chose the most recent or largest
population. When a study reported the results on different
subpopulations, we treated it as separate studies in the
meta-analysis.
Inclusion and exclusion criteria
Studies included in the meta-analysis were required to
meet the following criteria: (1) case–control or cohort
studies which evaluated the association between NQO1
Pro187Ser polymorphism and breast cancer risk; (2)
used an unrelated case–control design; (3) had an odds
ratio (OR) with 95% confidence interval (CI) or other
available data for estimating OR (95% CI); and (4) the
control population did not contain malignant tumor pa-
tients. Studies were excluded if one of the following
existed: (1) no control population; (2) duplicate of pre-
vious publication; and (3) insufficient information for
data extraction.
Data extraction
Two authors (Qiliu Peng and Xue Qin) independently
reviewed and extracted data from all eligible studies. Data
extracted from eligible studies included the first author,
year of publication, ethnicity, country of origin, geno-
typing method, source of control, matching criteria, breast
cancer ascertainment, total numbers of cases and controls
Table 1 Scale for quality assessment
Criteria Score
Representativeness of cases
Selected from cancer registry or multiple cancer center sites 2
Selected from oncology department or cancer institute 1




Population or community based 2
Both population-based and hospital-based/healthy volunteers/
blood donors
1.5
Hospital-based controls without breast cancer 1
Cancer-free controls without total description 0.5
Not described 0
Ascertainment of breast cancer
Histological or pathological confirmation 2






Quality control of genotyping methods





Hardy-Weinberg equilibrium in controls 1
Hardy-Weinberg disequilibrium in controls 0.5
No checking for Hardy-Weinberg disequilibrium 0
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backgrounds were categorized as Caucasian, Asian, and
Arab. When a study did not state the ethnic descendent
or if it was impossible to separate participants according
to such phenotype, the group reported was termed as
“mixed ethnicity”. To ensure the accuracy of the informa-
tion extracted, the two authors checked the data extrac-
tion results and reached consensus on all of the items. If
different results generated, they would check the data
again and have a discussion to come to an agreement. If
these two authors could not reach a consensus, another
author (Shan Li) was consulted to resolve the dispute and
a final decision was made by the majority of the votes.
Menopausal status was divided into premenopausal and
postmenopausal and was additionally recorded for strati-
fied analysis.
Quality score evaluation
The quality of eligible studies was evaluated independ-
ently by two authors (Qiliu Peng and Yu Lu) according
to a set of predefined criteria (Table 1) based on the
scale of Thakkinstian et al. [20]. The revised criteria
cover the source of controls, representativeness of cases,
ascertainment of breast cancer, total sample size, quality
control of genotyping methods, and Hardy-Weinberg
equilibrium (HWE) in the control population. Discre-
pancies were resolved by consensus. Scores ranged from
0 (lowest) to 10 (highest). Articles with scores equal to
or higher than 7 were considered “high-quality” studies,
whereas those with scores less than 7 were considered
“low-quality” studies.
Statistical analysis
The strength of the association between NQO1 Pro187Ser
polymorphism and breast cancer risk was assessed by
odds ratios (ORs) with 95% confidence intervals (CIs).
The significance of the pooled OR was determined by a
Z test and the p value less than 0.05 was considered sig-
nificant. The association of NQO1 Pro187Ser poly-
morphism with breast cancer risk was assessed using co-
dominant model (Ser/Ser vs. Pro/Pro and Ser/Pro vs. Pro/
Pro), recessive model (Ser/Ser vs. Ser/Pro + Pro/Pro), and
dominant model (Ser/Ser + Ser/Pro vs. Pro/Pro).
The χ2 based Q test was used to assess the heterogeneity
among studies [21,22]. If the result of the Q test was
PQ < 0.1, indicating the presence of heterogeneity, a ran-
dom-effects model (the DerSimonian and Laird method)
was used to estimate the summary ORs [21]; otherwise,
when the result of the Q test was PQ ≥ 0.1, indicating the
absence of heterogeneity, the fixed-effects model (the
Mantel–Haenszel method) was used [22]. To explore the
sources of heterogeneity among studies, we performed
logistic metaregression and subgroup analyses. The fol-
lowing study characteristics were included as covariates inthe metaregression analysis: genotyping methods (PCR-
RFLP vs. not PCR-RFLP), ethnicity (Caucasians vs. not
Caucasians), source of controls (Hospital-based vs. Popula-
tion-based), quality scores (High-quality vs. Low-quality),
HWE status (Yes vs. No), and breast cancer ascertainment
(pathologically or histologically confirmed vs. other diag-
nosis criteria). Subgroup analyses were conducted by eth-
nicity, menopausal status, quality score, source of control,
and HWE in controls. Galbraith plots analysis was per-
formed for further exploration of the heterogeneity.
Sensitivity analysis was performed by sequential removal
of individual studies. Publication bias was evaluated using
a funnel plot and Egger’s regression asymmetry test. The
distribution of the genotypes in the control population
was tested for HWE using a goodness-of-fit χ2 test. All
analyses were performed using Stata software, version
12.0 (Stata Corp., College Station, TX).
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Study characteristics
Base on our search criterion, 112 individual records were
found, but only 11 full-text publications were preliminarily
identified for further detailed evaluation. According to the
exclusion criteria, 2 publications were excluded including 1
provide insufficient information for data extraction [23],
and 1 was a meta-analysis [17]. Manual search of references
cited in the published studies did not reveal any additional
articles. As a result, a total of 9 relevant studies met the in-
clusion criteria for the meta-analysis [3,14-16,18,19,24-26].
Among them, one of the eligible studies contained data on
two ethnic groups [15], and we treated it independently.
Therefore, a total of 10 separate comparisons including
2,773 breast cancer cases and 4,076 controls were finally
included in our meta-analysis. The main characteristics of
the studies are presented in Table 2. Of all the eligible
studies, 6 were conducted in Caucasian populations,
3 were in Asians, and 1 was in Arabs. Six studies were
population–based and 4 were hospital–based studies.
All studies used validated methods including PCR-RFLP,
PCR-SSCP, PCR-CTPP, TaqMan assay, and 5′ exonuclease
assay to genotype the NQO1 Pro187Ser polymorphism.
The breast cancer cases were histologically or patholo-
gically confirmed in 7 of the eligible studies. The genotype
distributions of the controls in 2 studies were not con-
sistent with HWE [16,25].
Meta-analysis
The results of meta-analysis of the association between
NQO1 Pro187Ser polymorphism and breast cancer risk
were shown in Table 3. We did not observe a significant







Yao 2013 China Asian TaqMan Assay Age










America Caucasian PCR-SSCP Age, reg
Singh 2010 India Asian PCR-RFLP Age, smo
region
Hamajima 2002 Japan Asian PCR-CTPP NA
Sarmanova 2004 Czech Caucasian PCR-RFLP Age, ethn
Aston 2005 America Caucasian PCR-RFLP Age, reg
Hong 2007 America Caucasian TaqMan Assay Age, ethn
Lajin 2013 Syria Arab ARMS-PCR Ethnici
BC, Breast cancer; HC, Histologically confirmed; PC, Pathologically confirmed; NA, Not a
equilibrium in control population; PCR–RFLP, Polymerase chain reaction-restriction frag
conformation polymorphism; PCR-CTPP, polymerase chain reaction with confronting twand breast cancer risk when all studies were pooled into
the meta-analysis (Ser/Ser vs. Pro/Pro: OR = 1.251, 95% CI
0.843–1.856, P = 0.266; Ser/Pro vs. Pro/Pro: OR = 1.015,
95% CI 0.860–1.198, P = 0.860; Ser/Ser + Ser/Pro vs. Pro/
Pro: OR = 1.058, 95% CI 0.899–1.245, P = 0.498; Ser/Ser
vs. Ser/Pro + Pro/Pro: OR = 1.317, 95% CI 0.919–1.887,
P = 0.133). In subgroup analysis by ethnicity, statistical
significant increased breast cancer risk was found in
Caucasians (Ser/Pro vs. Pro/Pro: OR = 1.145, 95% CI =
1.008–1.301, P = 0.038; Ser/Ser + Ser/Pro vs. Pro/Pro:
OR = 1.177, 95% CI = 1.041–1.331, P = 0.009; Figure 1),
but not in Asians and Arabs. In stratified analysis by
source of control, significant increased breast cancer risk
was also found in population-based studies (Ser/Pro vs.
Pro/Pro: OR = 1.180, 95% CI = 1.035–1.344, P = 0.013; Ser/
Ser + Ser/Pro vs. Pro/Pro: OR = 1.191, 95% CI = 1.050–
1.350, P = 0.007; Figure 2), but not in hospital-based stu-
dies. However, when stratified by menopausal status,
quality score, and HWE in controls, statistical significant
association was not detected in all subgroups.
Test of heterogeneity
Statistical significant heterogeneity among studies was
observed when all studies were pooled into the meta-
analysis (Ser/Ser vs. Pro/Pro: PQ = 0.004; Ser/Pro vs. Pro/
Pro: PQ = 0.033; Ser/Ser + Ser/Pro vs. Pro/Pro: PQ = 0.023;
Ser/Ser vs. Ser/Pro + Pro/Pro: PQ = 0.007; Table 3). To ex-
plore the sources of heterogeneity, we performed metare-
gression and subgroup analyses. Metaregression analysis
of data showed that the genotyping methods, source of
controls, ethnicity, quality scores, HWE status, and breast
cancer ascertainment were not effect modifiers of he-













162/190 HB PC 7 0.540
218/424 PB HC 7.5 0.175
ion 190/231 PB HC 7 0.650
ion 346/235 PB HC 6 0.869
king, 200/200 HB Other 5.5 0.000
237/640 HB HC 6 0.046
icity 238/310 HB HC 6 0.576
ion 564/1212 PB Other 8.5 0.549
icity 496/495 PB Other 7 0.531
ty 122/139 PB HC 7.5 0.253
vailable; PB, Population–based; HB, Hospital–based; HWE, Hardy–Weinberg
ment length polymorphism; PCR-SSCP, Polymerase chain reaction-single strand
o-pair primers; ARMS-PCR, amplification refractory mutation system-PCR.
Table 3 Meta-analysis of NQO1 Pro187Ser polymorphism and breast cancer risk
Analysis No. of
studies
Ser/Ser vs. Pro/Pro (Homozygote) Ser/Pro vs. Pro/Pro (Heterozygote) Ser/Ser + Ser/Pro vs. Pro/Pro
(Dominant model)
Ser/Ser vs. Ser/Pro + Pro/Pro (Recessive model)
OR (95% CI) P/PQ OR (95% CI) P/PQ OR (95% CI) P/PQ OR (95% CI) P/PQ
Overall 10 1.251 (0.843-1.856) 0.266/0.004 1.015 (0.860-1.198) 0.860/0.033 1.058 (0.899-1.245) 0.498/0.023 1.317 (0.919-1.887) 0.133/0.007
Ethnicity
Caucasian 6 1.725 (0.884-3.368) 0.110/0.003 1.145 (1.008-1.301) 0.038/0.505 1.177 (1.041-1.331) 0.009/0.358 1.654 (0.847-3.232) 0.141/0.003
Asian 3 0.785 (0.571-1.080) 0.137/0.676 0.926 (0.771-1.124) 0.309/0.225 0.941 (0.790-1.129) 0.310/0.536 1.008 (0.765-1.329) 0.955/0.195
Arab 1 1.362 (0.525-3.533) 0.526/─ 1.168 (0.687-1.986) 0.565/─ 1.202 (0.731-1.976) 0.469/─ 1.290 (0.506-3.286) 0.594/─
Menopausal status
Premenopausal 2 1.124 (0.681-1.853) 0.648/0.299 1.110 (0.900-1.368) 0.330/0.431 1.104 (0.902-1.352) 0.337/0.604 1.160 (0.719-1.871) 0.544/0.147
Postmenopausal 2 0.637 (0.356-1.140) 0.129/0.833 0.950 (0.737-1.225) 0.694/0.187 0.918 (0.718-1.174) 0.495/0.113 0.762 (0.445-1.305) 0.322/0.482
Quality score
≥7 6 1.287 (0.746-2.221) 0.364/0.112 1.062 (0.864-1.307) 0.567/0.376 1.107 (0.897-1.365) 0.343/0.147 1.315 (0.817-2.117) 0.260/0.231
<7 4 1.251 (0.627-2.496) 0.524/0.021 0.942 (0.698-1.271) 0.694/0.070 0.983 (0.738-1.309) 0.906/0.071 1.368 (0.701-2.669) 0.358/0.015
Source of control
HB 4 1.099 (0.604-2.001) 0.757/0.017 0.966 (0.823-1.140) 0.311/0.301 0.912 (0.744-1.125) 0.179/0.252 1.344 (0.784-2.304) 0.283/0.015
PB 6 1.419 (0.802-2.511) 0.230/0.124 1.180 (1.035-1.344) 0.013/0.782 1.191 (1.050-1.350) 0.007/0.385 1.335 (0.767-2.323) 0.308/0.230
HWE in controls
Yes 8 1.450 (0.878-2.395) 0.147/0.004 1.080 (0.906-1.287) 0.389/0.069 1.136 (0.964-1.340) 0.128/0.079 1.463 (0.931-2.299) 0.099/0.011
No 2 0.791 (0.539-1.162) 0.232/0.378 0.800 (0.609-1.050) 0.108/0.389 0.788 (0.609-1.021) 0.091/0.607 0.926 (0.656-1.308) 0.663/0.105















Figure 1 Forest plots of the NQO1 Pro187Ser polymorphism and breast cancer risk in the overall populations. A. Forest plot for additive
model Ser/Pro vs. Pro/Pro using a fixed-effect model; B. Forest plot for dominant model Ser/Ser + Ser/Pro vs. Pro/Pro using a fixed-effect model.
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HWE status showed that heterogeneity still existed among
Caucasians, low quality studies, population-based studies,
and studies consistent with HWE (Table 2). To further ex-
plore the source of heterogeneity, we performed Galbraith
plots analysis to identify the outliers which might con-
tribute to the heterogeneity. Our results showed that the
study Menzel et al. [15] was the outlier in the overall
populations. All PQ values were greater than 0.10 after
excluding the study Menzel et al. [15] in the overall popu-
lations, Caucasians, population-based studies, and studies
consistent with HWE. However, the significance of the
summary ORs for NQO1 Pro187Ser polymorphism in the
overall population and subgroup analyses were not in-
fluenced by omitting this study [15].Figure 2 Forest plots of the NQO1 Pro187Ser polymorphism and brea
additive model Ser/Pro vs. Pro/Pro using a fixed-effect model; B. Forest plo
model.Sensitivity analysis
Sensitivity analysis was performed to assess the influence
of each individual study on the pooled ORs by sequential
removal of individual studies. The results suggested that
no individual study significantly affected the pooled ORs.
In addition, sensitivity analysis was further performed by
omitting the studies by Singh et al. [16] and Hamajima
et al. [25] in which the control populations were not in ac-
cordance with HWE. The significance of all ORs was not
altered after excluding these two studies (data not shown),
indicating that our results were robust and reliable.
Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of literatures in all comparisonst cancer risk in population-based studies. A. Forest plot for
t for dominant model Ser/Ser + Ser/Pro vs. Pro/Pro using a fixed-effect
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evidence of obvious asymmetry. Then, the Egger’s test
was used to provide statistical evidence of funnel plot
symmetry. The results still did not suggest any evidence
of publication bias (P = 0.114 for Ser/Ser vs. Pro/Pro;
P = 0.277 for Ser/Pro vs. Pro/Pro; P = 0.704 for Ser/Ser +
Ser/Pro vs. Pro/Pro, Figure 3; P = 0.226 for Ser/Ser vs.
Ser/Pro + Pro/Pro).
Discussion
Previous studies investigating the associations between
NQO1 Pro187Ser polymorphism and breast cancer pre-
sented inconsistent results, and most of those studies in-
volved no more than a few hundred breast cancer cases,
which is too few to assess any genetic effects reliably.
Meta-analysis has been recognized as an important tool to
more precisely define the effect of selected genetic poly-
morphisms on the risk for disease and to identify potential
important sources of between-study heterogeneity [27-29].
Hence, we performed this meta-analysis including all avail-
able studies to provide the most comprehensive assess-
ment of the associations between the NQO1 Pro187Ser
polymorphism and breast cancer risk. Our results showed
that the NQO1 is a candidate gene for breast cancer
susceptibility. The NQO1 Pro187Ser polymorphism was
associated with an increased breast cancer risk among
Caucasians (Ser/Pro vs. Pro/Pro: OR = 1.145, 95% CI =
1.008–1.301, P = 0.038; Ser/Ser + Ser/Pro vs. Pro/Pro:
OR = 1.177, 95% CI = 1.041–1.331, P = 0.009). Our result is
consistent with the previous meta-analysis performed by
Yuan et al. [17].
Given the biochemical properties of NQO1 in protec-
ting cells from oxidative damage and tumor development,Figure 3 Funnel plots for publication bias of NQO1 Pro187Ser polymor
model Ser/Ser + Ser/Pro vs. Pro/Pro: P = 0.704).this result may be biologically plausible. NQO1 is a key
enzyme which catalyzes the two-electron reduction of
quinoid compounds into hydroquinones, which reduces
and detoxifies quinines and thus protects cells against
redox cycling and oxidative stress [30,31]. Previous study
suggested that some variants, especially those in the pro-
moter regions of genes, may affect either the expression
or activity levels of enzymes and therefore may be mech-
anistically associated with cancer risk [32]. The NQO1
Pro187Ser polymorphism is a C-to-T transition in the
NQO1 gene which leads to a proline to serine amino acid
substitution at codon 187 in the protein [33,34]. The
NQO1 Pro187Ser polymorphism has been found corre-
lated with decreased enzymatic activity of NQO1 and may
affect host’s susceptibility to cancer by changing the
enzymatic activity of NQO1 [33,34]. More importantly,
the NQO1 Pro187Ser polymorphism has been shown
associated with increased risk for many different types of
cancers, including colorectal cancer [35], lung cancer [36],
esophageal cancer [37], and hepatocellular carcinoma [38].
Our results add new evidence that the NQO1 Pro187Ser
polymorphism contributes to cancer susceptibility.
In subgroup analysis stratified by ethnicity, the NQO1
Pro187Ser polymorphism presented a risk factor for
breast cancer in Caucasian populations, but not in Asian
and Arab subjects. The inconsistent data among the dif-
ferent ethnicities may indicate different effects of the
NQO1 Pro187Ser polymorphism on breast risk in dif-
ferent ethnic genetic and environmental backgrounds.
Studies reported that NQO1 enzyme not only detoxify
carcinogenic compounds [6] but also bioactivate several
kinds of procarcinogen [39]; thus, decreased activity of
NQO1 enzyme may have dual effect on carcinogenesis.phism and breast cancer risk in the overall populations (dominant
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Arab populations to detoxify carcinogenic compounds
which can effectively compensate for the loss of NQO1
enzyme activity. Nevertheless, owing to the limited num-
ber of relevant studies among Asian and Arab populations
included in the meta-analysis, the observed negative asso-
ciation between NQO1 Pro187Ser polymorphism and
breast cancer risk in Asians and Arabs is likely to be
caused by chance because study with small sample sizes
may have insufficient statistical power to detect a slight
effect or may have generated a fluctuated risk estimate.
Currently there are only 3 studies in Asian population and
1 in Arab population for NQO1 Pro187Ser polymorphism
and breast cancer risk. Therefore, the negative results of
the Asain and Arab populations should be interpreted
with caution.
In subgroup analysis according to the source of control,
statistical significant increased breast cancer risk was
found in population-based studies but not in hospital-
based studies. The reason may be that the hospital-based
studies have inherent selection biases due to the fact that
such controls may not be representative of the study
population or the general population, particularly when
the genotypes under investigation were associated with
the disease-related conditions that hospital-based controls
may have. Thus, the use of proper and representative
population-based control participants is of great impor-
tance in reducing biases in such genotype association
studies.
Heterogeneity is a potential problem when interpreting
the results of a meta-analysis, and finding the sources of
heterogeneity is one of the most important goals of meta-
analysis [40,41]. In the present study, statistical significant
between-study heterogeneity among studies was observed
when all studies were pooled into the meta-analysis
(Ser/Ser vs. Pro/Pro: PQ = 0.004; Ser/Pro vs. Pro/Pro:
PQ = 0.033; Ser/Ser + Ser/Pro vs. Pro/Pro: PQ = 0.023; Ser/
Ser vs. Ser/Pro + Pro/Pro: PQ = 0.007; Table 3). To explore
the sources of heterogeneity, we performed metare-
gression and subgroup analyses. Metaregression analysis
of data showed that the genotyping methods, ethnicity,
source of controls, quality scores, HWE status, and breast
cancer ascertainment were not effect modifiers of hetero-
geneity. Subgroup analyses stratified by ethnicity, meno-
pausal status, quality score, source of control, and HWE
status showed that heterogeneity still existed among
Caucasians, low quality studies, population-based studies,
and studies consistent with HWE (all PQ values < 0.10).
Subsequently, we performed Galbraith plots analysis to
further explore the source of heterogeneity. Galbraith
plots analysis showed that the study Menzel et al. [15] was
the outlier in all genetic models in the overall populations.
When excluding the study Menzel et al. [15], the hetero-
geneity decreased obviously and all PQ values were greaterthan 0.10 in all genetic comparison models in overall po-
pulations, Caucasians, population-based studies, and stu-
dies consistent with HWE. However, the summary ORs in
the overall populations, Caucasians, population-based
studies, and studies consistent with HWE were not mate-
rial changed by omitting this study, indicating that our re-
sults were robust and reliable. The results indicated that
the study Menzel et al. [15] was the major source of the
heterogeneity in the meta-analysis.
However, there are still some limitations in this meta-
analysis. First, in subgroup analysis by ethnicity, the in-
cluded studies regarded only Caucasians, Asians, and
Arabs for NQO1 Pro187Ser polymorphism. Data con-
cerning other ethnicities such as Africans were not
found. Thus, additional studies are warranted to evaluate
the effect of this functional polymorphism on breast
cancer risk in different ethnicities, especially in Africans.
Second, our results were based on unadjusted estimates.
We did not perform analysis adjusted for other covari-
ates such as age, obesity, drinking and smoking status,
use of contraceptives, environment factors, and so on,
because of the unavailable original data of the eligible
studies. Third, subgroup analyses were based on studies
with relevant information available. Owing to the lack of
detailed information in most studies, the subgroup ana-
lysis for menopausal status consisted of only two studies
for each subgroup, which might not be sufficient to
reach a reliable conclusion.
Conclusions
This meta-analysis provided a more precise estimation
based on larger sample size compared with the individual
studies and previous meta-analysis. Our study suggested
that NQO1 Pro187Ser polymorphism might contribute to
breast cancer risk, especially in Caucasian populations.
However, it is necessary to conduct large sample studies
using standardized unbiased genotyping methods, homo-
geneous breast cancer patients, and well-matched controls
to further validate the results of our meta-analysis. More-
over, gene-gene and gene-environment interactions should
also be considered in the analysis. Such studies taking
these factors into account may eventually lead to a better,
more comprehensive understanding of the association
between NQO1 Pro187Ser polymorphism and breast can-
cer risk.
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